Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. [electronic resource]
Producer: 20031103Description: 628-34 p. digitalISSN:- 1097-6744
- Abciximab
- Angina, Unstable
- Angioplasty, Balloon, Coronary
- Antibodies, Monoclonal -- adverse effects
- Anticoagulants -- adverse effects
- Coronary Disease -- complications
- Drug Therapy, Combination
- Enoxaparin -- adverse effects
- Eptifibatide
- Female
- Fibrinolytic Agents -- adverse effects
- Hemorrhage -- chemically induced
- Heparin, Low-Molecular-Weight -- adverse effects
- Humans
- Immunoglobulin Fab Fragments -- adverse effects
- Male
- Middle Aged
- Myocardial Infarction -- complications
- Peptides -- adverse effects
- Platelet Aggregation Inhibitors -- adverse effects
- Platelet Glycoprotein GPIIb-IIIa Complex -- antagonists & inhibitors
- Syndrome
- Thrombolytic Therapy
- Tirofiban
- Treatment Outcome
- Tyrosine -- adverse effects
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.